Abstract
Persons with psychiatric diagnoses are at a disproportionately high risk for cardiovascular disease mediated by the cardiovascular-kidneymetabolic syndrome. While lifestyle interventions are foundational for promoting heart health, behavioral initiatives alone often fall short in achieving attainable goals. GLP-1 receptor agonists are now FDA approved for treating obesity and diabetes mellitus. Statins are available for treating dyslipidemia to targets in the PREVENT risk calculator in the 2026 guidelines of the American Heart Association (AHA). Low-dose aspirin use is currently recommended for persons at intermediate risk by the American College of Cardiology (ACC). Such use by persons with subclinical coronary atherosclerosis identified by coronary artery calcium scoring (CACS) likely provides enhanced prevention. Incorporating these approaches into the primary care of psychiatric patients may thereby mitigate excess morbidity and mortality due to atherosclerotic cardiovascular disease (ASCVD) associated with psychiatric disorders
Keywords
Primary cardiovascular prevention, Psychiatric disorders